Disease relevance of Hydroxypropiophenone

• This study is an evaluation of a rapid technique for the differentiation of the Mycobacterium tuberculosis complex from other mycobacteria, using p-nitro-alpha-acetylamino-beta- hydroxypropiophenone (NAP) as a selective inhibitory agent [1].
• Synthetic antioxidants: EPO (p-ethoxyphenol), PHP (p-hydroxypropiophenone), and DPPD (N,N'-diphenyl-p-phenylenediamine) dissolved in dimethylsulfoxide were administered subcutaneously to mice after subcutaneous implantation of Lewis lung carcinoma or amelanotic B16 melanoma into the tails [2].

High impact information on Hydroxypropiophenone

• Compound 3 was obtained via a concise seven step synthesis starting from palladium-catalyzed carbonylation of 4-propionylphenol, followed by a Wittig reaction with 2,4-diamino-5-(chloromethyl)furo[2,3-d]pyrimidine (6), catalytic hydrogenation, hydrolysis, and standard peptide coupling with diethyl L-glutamate [3].
• A sex-difference in the conversion of diethylstilboestrol epoxide into 4'-hydroxypropiophenone and to polar and water-soluble products was observed [4].
• Transport rates through the 1540 and 1000 copolymer membranes were in decreasing order: paroxypropione greater than 5-nitrosalicylic acid greater than sulfaguanidine greater than phenylbutazone; however, through the 600 copolymer membrane the rates were paroxypropione greater than 5-nitrosalicylic acid approximately sulfaguanidine [5].
• Treatment of RBL-1, a rat basophilic cell line, cells with malathion, parathion or paroxon in vitro also led to the release of beta-hexosaminidase with paraoxon being the most potent [6].

References